Race Oncology Limited
Race Oncology Limited, a clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments. The company's lead product is bisantrene, a small molecule chemotherapeutic that has a clinical history with demonstrated therapeutic benefits in adult and paediatric patients. It is advancing reformulated bisantrene (RC220) to address the unmet need… Read more
Race Oncology Limited (RAONF) - Total Assets
Latest total assets as of June 2024: $20.23 Million USD
Based on the latest financial reports, Race Oncology Limited (RAONF) holds total assets worth $20.23 Million USD as of June 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Race Oncology Limited - Total Assets Trend (2013–2024)
This chart illustrates how Race Oncology Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Race Oncology Limited - Asset Composition Analysis
Current Asset Composition (June 2024)
Race Oncology Limited's total assets of $20.23 Million consist of 86.1% current assets and 13.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 85.0% |
| Accounts Receivable | $105.69K | 0.5% |
| Inventory | $-105.69K | -0.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $2.81 Million | 13.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Race Oncology Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Race Oncology Limited's current assets represent 86.1% of total assets in 2024, a decrease from 100.0% in 2013.
- Cash Position: Cash and equivalents constituted 85.0% of total assets in 2024, down from 99.0% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 13.0% of total assets, an increase from 0.0% in 2013.
- Asset Diversification: The largest asset category is intangible assets at 13.9% of total assets.
Race Oncology Limited Competitors by Total Assets
Key competitors of Race Oncology Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Race Oncology Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Race Oncology Limited generates 0.20x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Race Oncology Limited is currently not profitable relative to its asset base.
Race Oncology Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.32 | 20.44 | 5.33 |
| Quick Ratio | 9.38 | 20.44 | 5.33 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $15.55 Million | $ 22.39 Million | $ 831.97K |
Race Oncology Limited - Advanced Valuation Insights
This section examines the relationship between Race Oncology Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 16.65 |
| Latest Market Cap to Assets Ratio | 7.24 |
| Asset Growth Rate (YoY) | -24.1% |
| Total Assets | $20.23 Million |
| Market Capitalization | $146.53 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Race Oncology Limited's assets at a significant premium ( 7.24x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Race Oncology Limited's assets decreased by 24.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Race Oncology Limited (2013–2024)
The table below shows the annual total assets of Race Oncology Limited from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-06-30 | $20.23 Million | -24.06% |
| 2023-06-30 | $26.64 Million | -29.01% |
| 2022-06-30 | $37.52 Million | +163.41% |
| 2021-06-30 | $14.25 Million | +140.08% |
| 2020-06-30 | $5.93 Million | +13.19% |
| 2019-06-30 | $5.24 Million | -36.39% |
| 2018-06-30 | $8.24 Million | +37.32% |
| 2017-06-30 | $6.00 Million | +34.26% |
| 2016-06-30 | $4.47 Million | +3490.93% |
| 2015-06-30 | $124.47K | +101.40% |
| 2014-06-30 | $61.80K | -41.27% |
| 2013-06-30 | $105.23K | -- |